Hisanori Muto

6PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gastroenterology and hepatologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 28, 2026
The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

Mizuki Ariga, Teiji Kuzuya, Hisanori Muto

|Nov 27, 2025
Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi

|Aug 28, 2025
Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma.

Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa

|Jun 02, 2025
Alcoholic Hepatitis in a Japanese Hospital: Losing Contact With Some Patients After Delirium Tremens May Lead to Missed Critical Events.

Hisanori Muto, Teiji Kuzuya, Yoshihiko Tachi

|Mar 29, 2023
Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet.

Hisanori Muto, Takashi Honda, Taku Tanaka

|Nov 12, 2019
Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report.

Hisanori Muto, Teiji Kuzuya, Takanori Ito

Pageof 1

Frequent Collaborators

2 joint publications

Kazunori Nakaoka

2 joint publications

Teiji Kuzuya

1 joint publications

Taku Tanaka

1 joint publications

Shinya Yokoyama